No—only 7% of women in one database had a recorded eye exam in the first year after starting treatment. The report looked at 2,327 women prescribed Tamoxifen, a medicine that blocks estrogen’s effect on breast tissue. Researchers used the US National Institutes of Health’s All of Us database. They checked whether women had seen an eye care provider after starting treatment. Only 162 women had a recorded visit within that first year. Just 1.7% had a retinal exam during the same 12 months. That exam checks the light-sensitive tissue at the back of the eye. The article highlights these low rates because women using the medicine face a higher risk of damage to that tissue. The key finding is about recorded eye checks, not how often eye damage happened. The supplied report does not give numbers for vision changes or eye damage. It also does not explain why so few exams were recorded. These figures alone cannot show whether every missing record means a missed visit. For BioSocial members, this adds another layer to tracking a medication routine. Bloodwork results are one part of a health record; exam dates are another. A personal timeline could include the treatment start date, eye visit dates, and exam findings. Comparing notes with the community may help reveal what follow-up has looked like for others, without treating this group’s rates as anyone’s personal risk. What has eye screening looked like during your Tamoxifen routine, including the timing of your first exam?